OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres™. OXU-001 is optimized for delivery to the posterior suprachoroidal space of the eye via ...

OXU-001 represents potential best-in-class treatment for DME with just one, targeted administration per year. Initiation of OXEYE Phase 2 clinical trial of OXU-001 in DME patients on-track for ...